AMENDMENT FOR PRINTED BILL
23ja
___________________ moved that SB 23 be amended as follows:
On page 3, line 9, of the printed bill, after "Cathinone" insert "
and other variations, defined as
any compound, material, mixture, preparation or other product unless listed in another schedule or
an approved FDA drug (e.g. buproprion, pyrovalerone), structurally derived from
2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring
systems, whether or not the compound is further modified in any of the following ways:
(a) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the
ring system by one or more other univalent substitutents;
(b) By substitution at the 3-position with an acyclic alkyl substituent;
(c) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
methoxybenzyl groups or by inclusion of the 2-amino nitrogen atom in a cyclic
structure.
Some trade or other names: methcathinone, 4-methyl-N-methylcathinone (mephedrone);
3,4-methylenedioxy-N-methylcathinone (methylone); 3,4-methylenedioxypyrovalerone
(MDPV); Naphthylpyrovalerone (naphyrone); 4-flouromethcathinone (flephedrone);
4-methoxymethcathinone (methedrone; Bk-PMMA); Ethcathinone (N-Ethylcathinone);
3,4-methylenedioxyethcathinone (ethylone);
Beta-keto-N-methyl-3,4-benzodioxyolybutanamine (butylone); N,N-dimethylcathinone
(metamfepramone); Alpha-pyrrolidinopropiophenone (alpha-PPP);
4-methoxy-alpha-pyrrolidinopropiophenone (MOPPP);
3,4-methylenedioxyalphapyrrolidinopropiophenone (MDPPP);
Alpha-pyrrolidinovalerophenone (alpha-PVP); 3-fluoromethcathinone;
4'-Methyl-?-pyrrolidinobutiophenone (MPBP)".
On page 3, line 10, overstrike everything after "(38)" .
On page 3, line 11, overstrike "(39)".
On page 3, line 12, overstrike "(40)" and insert "(39)".
On page 3, line 13, overstrike "(41)" and insert "(40)".
On page 3, line 14, overstrike "(42)" and insert "(41)".
On page 3, line 15, overstrike "(43)" and insert "(42)".
On page 3, line 16, overstrike "(44)" and insert "(43)".
On page 3, line 17, overstrike "(45)" and insert "(44)".
On page 3, delete lines 18 to 24, inclusive, and insert:
"
(46)(45) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
(47) 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;
(48) 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;
(49) 1-Butyl-3-(1-naphthoyl)indole;
(46) Synthetic cannabinoids. Any material, compound, mixture, or preparation that is not listed
as a controlled substance in another schedule, is not an FDA-approved drug, and contains
any quantity of the following substances, their salts, isomers (whether optical, positional,
or geometric), homologues, and salts of isomers and homologues, unless specifically
excepted, whenever the existence of these salts, isomers, homologues, and salts of
isomers and homologues is possible within the specific chemical designation:
(a) Naphthoylindoles. Any compound containing a 3-(1-naphthoyl)indole structure
with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinhyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring
to any extent and whether or not substituted in the naphthyl ring to any extent.
Some trade or other names: JWH-015; 1-pentyl-3-(1-naphthoyl)indole (JWH-018);
1-hexyl-3-(1-naphthoyl)indole (JWH-019); 1-butyl-3-(1-naphthoyl)indole
(JWH-073); 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081);
1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200); JWH-210;
JWH-398; 1-pentyl-3-(1-naphthoyl)indole (AM-678);
1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201); WIN 55-212;
(b) Naphthylmethylindoles. Any compound containing a
1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not
further substituted in the indole ring to any extent and whether or not substituted
in the naphthyl ring to any extent;
(c) Phenylacetylindoles. Any compound containing a 3-phenylacetylindole structure
with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring
to any extent and whether or not substituted in the phenyl ring to any extent.
Some trade or other names: 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole
(SR-18); 1-cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8);
1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203);
(d) Benzoylindoles. Any compound containing a 3-(benzoyl)indole structure with
substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl,
cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring
to any extent and whether or not substituted in the phenyl ring to any extent.
Some trade or other names: 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
1-pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19); Pravadoline (WIN 48,098);
1-pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4);
(e) Naphthoylpyrroles. Any compound containing a 3-(1-naphthoyl)pyrrole structure
with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl,
alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or
2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring
to any extent and whether or not substituted in the naphthyl ring to any extent.
Some trade or other names: JWH-307;
(f) Naphthylmethylindenes. Any compound containing a naphthylideneindene
structure with substitution at the 3-position of the indene ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not
further substituted in the indene ring to any extent and whether or not substituted
in the naphthyl ring to any extent;
(g) Cyclohexylphenols. Any compound containing a 2-(3-hydroxycyclohexyl)phenol
structure with substitution at the 5-position of the phenolic ring by an alkyl,
haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not
substituted in the cyclohexyl ring to any extent.
Some trade or other names:
5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47, 497 and
homologues, which includes C8); cannabicyclohexanol;
(h) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Some trade or other names:
HU-210;
(i) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone. Some trade or other names: WIN 55, 212-2;
(47) 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine) (MDAI);
(48) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(49) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D);
(50) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(51) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(52) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2);
(53) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
(54) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(55) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); and
(56) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)".
On page 4, delete lines 1 to 5, inclusive, and insert:
"
(50) 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole; and
(51) 1-Pentyl-3-(1-naphthoyl)indole.".
On page 7, delete line 20, and insert:
"
(46) Ezogabine,[N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester],".